Jonathan H. Rayment

A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Edith T. Zemanick, Jennifer L. Taylor‐Cousar, Jane C. Davies et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 288 citations · Full text

Pharmacy, Pediatrics, Pharmacology +15

Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2–5 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele

Jennifer L. Goralski, Jordana E. Hoppe, Marcus Mall et al. · American Journal of Respiratory and Critical Care Medicine · 2023 · 129 citations · Full text

Pharmacy, Pediatrics, Pharmacology +15

Protocols for multi‐site trials using hyperpolarized ¹²⁹Xe MRI for imaging of ventilation, alveolar‐airspace size, and gas exchange: A position paper from the ¹²⁹Xe MRI clinical trials consortium

Peter Niedbalski, Chase Hall, Mario Castro et al. · Magnetic Resonance in Medicine · 2021 · 102 citations · Full text

Medicine, Nuclear Medicine, Radiology +17

Hyperpolarised¹²⁹Xe magnetic resonance imaging to monitor treatment response in children with cystic fibrosis

Jonathan H. Rayment, Marcus J. Couch, Nancy McDonald et al. · European Respiratory Journal · 2019 · 85 citations · Full text

Medicine, Pediatrics, Radiology +17

Comparison of Functional Free-Breathing Pulmonary 1H and Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Cystic Fibrosis

Marcus J. Couch, Samal Munidasa, Jonathan H. Rayment et al. · Academic Radiology · 2020 · 67 citations · Full text

Medicine, Pediatrics, Radiology +12